Archive for February, 2010

Psychiatry completes their mission to pathologize every single human behavior into a mental disorder with new DSM

Saturday, February 13th, 2010

The Sunday Times
By Lois Rogers
February 14, 2010

Psychiatrists are to give official recognition to dozens of new mental disorders, including a condition nicknamed “Mary Whitehouse syndrome” — the thrill of being appalled by pornography and other obscenities.

Absexuality appears to have been inspired by the zeal of Whitehouse, the campaigner who railed against smut on television.

The condition is one of many mood disorders and personality traits that are likely to be added to the next edition of the psychiatrists’ “bible”.

The disorders, which also include hypersexuality — the desire for multiple partners, perhaps characterised by the golfer Tiger Woods — reflect changing social patterns.

However, critics believe their classification as psychiatric problems may lead them to be exploited for profit by drug companies.

Other new conditions include sluggish cognitive tempo disorder, which some would regard as simple laziness, and relational disorder, in which two people — often a separating couple — struggle to get on.

People who whinge constantly may be suffering negativistic personality disorder. Intermittent explosive disorder — otherwise known as adult tantrums — is also defined for the first time.

The conditions are named in a draft version of the Diagnostic and Statistical Manual of Mental Disorders , a key reference book for psychiatrists for more than 50 years.

Read entire article:  http://www.timesonline.co.uk/tol/life_and_style/health/article7026324.ece

« Return to news items


Share

UN Children’s Rights Committee Has “Serious Concerns” About Kids Being Drugged With Ritalin & Other Psychostimulants

Friday, February 12th, 2010

By CCHR Int
February 12, 2010

On January 29, 2010, the United Nations Committee on the Rights of the Child (CRC) issued a formal statement that it is “seriously concerned about studies that indicate the rapid increase within a short period of time of the prescription of psycho-stimulants such as Ritalin and Concerta to children diagnosed with ADHD.”[1]

The Committee met in Geneva to review Norway’s implementation of the UN Convention on the Rights of the Child and was responding to the 10-fold increase in psychostimulants prescribed children in the country between 1991 and 2003 and a further 70% since 2004.  Big Pharma has been reaping the profits from this—sales of psychostimulants increased more than 4,000% during the last decade. It was the third Nordic country the Committee had investigated for its psychiatric drugging of children.

Norwegian government delegates, including the Minister of Children, Audun Lyskbakken, and representatives of the Department of Health were strongly questioned about the potential abuse of children with powerful stimulants.  In a twitter message from the hearing the Norway’s Ombudsman for children said Minister Lyskbakken was questioned about the soaring Ritalin usage and whether children’s diets may be the source of “ADHD” symptoms resulting in prescriptions for stimulants. The Minister conceded, “There is room for improvement.”[2] The Norwegian Minister of Children also told the hearing that two studies are being conducted to establish the effectiveness of Omega 3 oils on the symptoms of “ADHD” and that medication should only be a last resort.

This is a step in the right direction of cocaine-like stimulants (that can cause psychosis, heart attacks and strokes) being prohibited for use in children, especially when there are safe non-drug alternatives.

Media reports on the CRC hearing and recommendations noted that expert testimony discussed evidence that diet is linked to behavior problems and questioned how Norway’s schools were tackling this. [3]

The CRC recommended that the government “carefully examine” the “phenomenon of over-prescription of psycho-stimulants to children” and to take initiatives to provide children with a greater range of educational and treatment options.

In 2005, the CRC completed a review of the implementation of human rights standards for children and issued a strong warning then to the governments that so-called ADHD and ADD are being misdiagnosed and that psychostimulant drugs are being over-prescribed, despite growing evidence of the harmful effects of these drugs.[4]


[1] UN Convention on the Rights of the Child, Committee on the Rights of the Child, “Main areas of concern and recommendations; Basic health and welfare, points 42 & 43.) 29 Jan, 2010.

[2] http://www.morsmal.org/cgi-bin/index.cgi?action=viewnews&id=1460

[3] United Nations, Committee on Rights of Child Examines Report of Norway, 21 Jan. 2010.

[4] “Considerations of reports under article 44 of the convention—Concluding observations: Finland,” UN Committee of the Rights of the Child, CRC/C/15/Add.272, 20 Oct. 2005, p. 7; “Considerations of reports under article 44 of the convention—Concluding observations: Denmark,” UN Committee of the Rights of the Child, CRC/C/DNK/CO/3, 25 Nov. 2005, p. 8.

« Return to news items


Share

Lawyer who took on drug giant Eli Lilly & won has a new target—the psychiatric industry & drugging of foster kids

Friday, February 12th, 2010

KTUU.com
By Rhonda McBride
February 11, 2010

ANCHORAGE, Alaska — An Alaska attorney who has gone up against a drug giant and won has a new target.

Jim Gottstein is taking on psychiatry in Alaska for over-prescribing medicine to children.

Gottstein was the attorney who forced Eli Lilly to pay more than $1 billion in settlements over the anti-psychotic drug Zyprexa.

He also heads up a group called the Law Project for Psychiatric Rights, which filed the lawsuit. The group claims over-prescribing is disabling children for life.

A growing number of children are prescribed psychiatric drugs, and a growing number of mental health advocates say we should be alarmed, because those drugs are often unnecessary

“They’re really a chemical lobotomy, because that’s what they do to the brain,” Gottstein said.

The list of those named in Gottstein’s lawsuit is long: More than a dozen child psychiatrists, health agencies, state officials, and pharmacies that include Walmart, Fred Meyer and Safeway.

“Eighteen-year-olds are having heart attacks from these drugs,” Gottstein said.

He says he’s tried to get the state and Alaska psychiatrists to use more restraint.

He says they are using powerful drugs on children that are intended for adults.

“People put on these drugs have a life expectancy of 25 years shorter than the general population. These drugs are so harmful, that they literally kill people,” Gottstein said.

Read entire article:  http://www.ktuu.com/Global/story.asp?S=11974882

« Return to news items


Share

How Pharma funded psychiatrists pathologize behavior as mental illness so more drugs can be marketed to the masses

Thursday, February 11th, 2010

EmaxHealth
By Tyler Woods Ph.D.
February 11, 2010

Critics such say there’s a damaging conflict of interest with the financial ties between drug companies and experts who are revising the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), as well as guidelines on the best treatments.

This question has been a big topic of debate not just in scientific and academic journals it also concerns the public welfare. This is because the experts are making it possible for financial profit to affect decisions about who needs treatment, whether they are prescribed medicine and which ones, says Lisa Cosgrove, a psychologist at the University of Massachusetts-Boston.

The DSM appears to be more a political document than a scientific one. Each diagnostic criteria in the DSM is not based on medical science. “No blood tests exist for the disorders in the DSM. It relies on judgments from practitioners who rely on the manual,” says Lisa Cosgrove of the University of Massachusetts Boston.

Approximately 160 experts are appointed by the American Psychiatric Association are updating the manual, expected in 2011-2012. For the first time the psychiatry association is now required to publicly disclose all industry ties. Sixty-eight percent of task-force members report economic ties with drug companies, Cosgrove says. These links include the experts being on corporate boards, hold stock or collect money as advisers for pharmaceutical companies.

Read entire article:  http://www.emaxhealth.com/1357/7/35563/experts-who-write-dsm-have-financial-ties-pharmaceutical-companies.html

« Return to news items


Share

Psychiatry’s New Billing Bible, The DSM: A Goldmine of Mental Disorders for Pharma

Wednesday, February 10th, 2010

By CCHR Int

The American Psychiatric Association’s release of the proposed fifth revision of its billing bible, the Diagnostic and Statistical Manual of Mental Disorders (DSM) fuels University of California’s  Dr. Irwin Savodnik’s statement, “The very vocabulary of psychiatry is now defined at all levels by the pharmaceutical industry.”

Take a look at some of psychiatry’s proposed mental disorders for their new manual and you can bet Pharma already has clinical drug trials in the works for such ludicrous mental “illnesses” as: Compulsive Shopping disorder, Skin Picking Disorder, Hoarding Disorder, Olfactory Reference Syndrome (smelling things not really there), Gender Identity Disorder, Impulse-Control Disorders Not Elsewhere Classified, and then there’s the redefinition of losing your cool: Temper Dysregulation (mood swings) Disorder with Dysphoria (abnormal discontent).  Add to that one of psychiatry’s latest drug sale boosters, Restless Leg Syndrome, newly added to the DSM.

The real danger of any revision of DSM, despite medicalizing all of life’s problems or idiosyncratic behaviors into a mental “disease” is that it is the primary feeder line for psychiatric drug sales.  Psychiatry’s 300% increase of mental disorders in the DSM over five decades has already generated billions of dollars in government funding—largely covering drug treatment.  Since DSM-IV in 1994, there has been a 256% increase in antipsychotics and antidepressants drug sales.  The diagnosis of so-called bipolar disorder has increased 4000%, with 2.5 million kids now on antipsychotic drugs that can cause life-threatening side effects including diabetes, fatal blood clots, cardiac arrest, suicidal thoughts and violence.

Despite major controversy and Senate investigations into psychiatry’s conflicts of interest (psychiatrists get more money from Pharma than any other medical specialty), psychiatrists participating in the DSM-V revision still have direct ties to Pharma: 18 of the 20 members overseeing the revision for treating just three “mental disorders” have financial ties to drug companies, with drug treatment for these disorders alone generating $25 billion a year in pharmaceutical sales.  Since 2008, the APA has been under U.S. Senate Finance Committee investigation for its conflicts of interest with the pharmaceutical industry, from which it derives a third of its annual income.

In the earlier revision, the Committee was rife with psychiatrists with undisclosed financial interests with pharmaceutical companies, with sales of drugs for conditions voted into the DSM resulting in more than $80 billion in revenue worldwide.

As the late Dr. Sydney Walker III, a neurologist and psychiatrist, wrote: “Drug company money influences every aspect of modern-day psychiatry. The American Psychiatric Association is literally built on a foundation of drug money…In return, the APA bends over backward to help drug companies promote their products.”[1] This habit looks more like one of the compulsions the APA tries so hard to foist off on others in its proposed new cookbook of mental disorders: DSM-V.

Further, the APA advises members about DSM-V: “when considering whether to add a mental/psychiatric condition to the nomenclature, or delete a mental/psychiatric condition from the nomenclature, potential benefits…should outweigh potential harms….” Emphasis added for a reason: delete a mental disorder?   If psychiatrists can simply delete  a mental disorder, does that mean that all the people previously diagnosed with the “illness” who were drugged and harmed, get to sue the APA for being fraudulently diagnosed?

As Lawrence Stevens, former Assistant District Attorney in California, stated in response to the APA “deleting” homosexuality as a mental disorder in 1973 (prompted only by activists protesting it): “If mental illness were really an illness in the same sense that physical illnesses are illnesses, the idea of deleting homosexuality or anything else from the categories of illness by having a vote would be as absurd as a group of physicians voting to delete cancer or measles from the concept of disease.”[2]

For more information on the DSM click here.


[1] Sydney Walker, III, M.D., A Dose of Sanity, (John Wiley & Sons, Inc, New York, 1996), p. 229.

[2] Lawrence Stevens, J.D., “Does Mental Illness Exist?,” undated article, Internet URL: http://www.mentalhealthfacts.com/antipsychiatry/exist.htm, accessed: 9 Jan. 2001.

« Return to news items


Share

The biggest Pharma Front Group of all—The American Psychiatric Association—unveil their newest invented mental disorders

Wednesday, February 10th, 2010

GoozNews
February 10, 2010

The American Psychiatric Association yesterday gave the press an advance view of its proposed Diagnostic and Statistical Manual of Mental Disorders, and the reports were highly skeptical. Will Tiger Woods soon be diagnosed with “hypersexual disorder”? He could be if the proposals go into effect. The APA will be accepting comments through April.

The news reports barely noted the fact that dozens of psychiatrists who serve on the DSM-V (it’s the fifth edition) task force and working groups have financial ties to the pharmaceutical and medical device industries, as well as to numerous patient advocacy groups, which themselves are often funded by industry. A quick check of the APA website reveals that none of the financial disclosures for committee members have been updated since 2008, when the committees were intially appointed.

The APA promises to “relaunch” the website later today. Hopefully, the update will include new biographies and financial disclosures for all the committee members. It is crucial that the disclosures include all relationships with industry during 2009 and 2010 — the period when the committees were actively engaged in coming up with the proposals.

Read entire article:  http://www.gooznews.com/node/3266

« Return to news items


Share

Scandalous abuse of the elderly: 100,000 prescribed antipsychotics that double risk of death/triple risk of stroke

Monday, February 8th, 2010

The Daily Telegraph
By Rebecca Smith
February 7, 2010

Tens of thousands of vulnerable dementia patients are being prescribed ‘chemical cosh’ drugs in hospital wards in a ‘scandalous abuse’ of the elderly, ten leading health organisations have said in a letter to The Daily Telegraph.

Three quarters of nurses have seen people with dementia in general wards in hospital prescribed antipsychotic drugs that are known to double the risk of death and triple the risk of a stroke in these patients, research has shown.

It is the first time the scale of the abuse in hospital wards is exposed, following warnings that 100,000 dementia patients in care homes are prescribed the drugs leading to the deaths of 23,000 a year.

Ten leading charities, carers groups and experts have written to The Daily Telegraph saying: “We cannot stand by while this scandalous abuse of vulnerable citizens continues.”

Neil Hunt, Chief Executive of Alzheimer’s Society said: “The massive over prescription of antipsychotics to people with dementia is an abuse of human rights, causing serious side effects and increasing risk of death. These powerful drugs should only be used in a small number of cases. The Government must take action to ensure that these drugs are only ever used as a last resort.”

They have called on the government to publish its long-overdue review of the use of antipsychotics which ministers promised would be out in May of this year.

Read entire article:  http://www.telegraph.co.uk/health/healthnews/6264962/Scandalous-abuse-of-the-elderly-prescribed-antipsychotics-in-hospital-exposed.html

« Return to news items


Share

Wake Up FDA—Even Drug Giants Are Admitting No Lab Tests Exist To Prove If Antidepressants Work

Friday, February 5th, 2010

By CCHR
February 5, 2010

With drug giant GlaxoSmithKline (GSK) now stating it will abandon future antidepressant research, one can only wonder if the U.S. Food and Drug Administration (FDA) noted GSK’s CEO Andrew Witty’s admission that it is “hard to prove that a depression drug is working” because “patient improvement is measured by subjective mood surveys, and not by the clear-cut blood tests and biological measures used in other diseases.”

To put this in perspective, the head of GSK is pointing out an obvious flaw in the psycho/pharmaceutical cash cow of psychiatric drugs.  There is no way to prove if a drug is working because there are no lab tests to prove anyone has a mental disorder in the first place—unlike medical diseases where blood and lab tests can show the effect of any drug upon the disease.

Given this statement, the next logical question is how did the FDA ever approve any psychiatric drug as safe and effective when the drug makers admit there is no proof of efficacy, only “subjective mood surveys.”

It seems the drug companies are catching on while the FDA is still promoting junk science in order to grant drug approval.

And that’s on top of the Journal of the American Medical Association (JAMA) landmark study published last month that found antidepressants no more effective than placebo. Add to that, 40% of antidepressant clinical trials have not been published because of negative results—they failed to show any significant benefit.  So, even with a “subjective mood survey,” they can’t get the drug to make the mark.  And the studies that did “prove” it did so, as Newsweek put it, for “the same reason why Disney’s Dumbo could initially fly only with a feather clutched in his trunk—believing makes it so.”

The FDA says: “Drugs must undergo a rigorous evaluation of safety, quality, and effectiveness before they can be sold.” Clearly, there is nothing rigorous about testing efficacy in antidepressants.  GSK’s confession is on par with former American Psychiatric Association president, Steven Sharfstein admitting that there is no lab test to confirm a chemical imbalance in the brain.  Reiterating this was his APA cohort Mark Graff, who told CBS Studio 2 that this theory was “probably drug industry derived”—in other words, a marketing ploy in the same vein as antidepressants are “effective.”

John Swann, Ph.D., historian at the FDA, once said: “To establish fraud, the bureau had to show that the manufacturer knew the product was worthless, and this proved difficult in many cases.”[i]

Well, FDA, if a drug company can admit what the FDA has known all along—that the efficacy of an antidepressant or any psychiatric drug is entirely subjective and, therefore, not based on science, how can the FDA continue to approve and condone the use of these drugs as “safe and effective?”

Instead of the potential fraud of a manufacturer, a more pertinent question we should be asking is this:
What if the government agency in charge of approving drugs, the FDA, knew a product was worthless and approved its use anyway? What happens then?


[i] http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/PromotingSafeandEffectiveDrugsfor100Years/default.htm

« Return to news items


Share

Glaxo stops antidepressant research: patient improvement can’t be measured w/ blood tests only subjective mood surveys

Friday, February 5th, 2010

Wall Street Journal
By Jeanne Whalen
February 5, 2010

GlaxoSmithKline PLC said it will stop research into new antidepressants and focus on diseases for which it believes it can develop more valuable drugs, a major shift for a company that developed some of the biggest-selling antidepressants of the past 20 years.

Profits at the U.K. drug giant, which posted a 66% increase in fourth-quarter earnings Thursday, were long fueled by the antidepressants Paxil and Wellbutrin, which at their peak generated billions of dollars a year in sales. Similar medicines, such as Eli Lilly & Co.’s Prozac and Pfizer Inc.’s Zoloft, also generated big sales for those companies.

However, low-cost generic copies have eroded demand for name-brand antidepressants, which accounted for just 2.3% of Glaxo’s total sales last year, down from 14% in 2002. Chief Executive Andrew Witty said Thursday that the company thinks further investment in the market wouldn’t be prudent.

Part of the reason is financial risk. Clinical trials of antidepressants are among the “most expensive and highest-risk” of all drug trials, Mr. Witty said, because companies often don’t know until the end of very large studies whether a drug works. It is also hard to prove that a depression drug is working, he said, because patient improvement is measured by subjective mood surveys, and not by the clear-cut blood tests and biological measures used in other diseases.

That’s a drawback in an era when insurers and other health-care payers want to see clear value for their money, Mr. Witty said.

Payers “want big benefits to make it worth their while to invest their resources,” he said, adding that Glaxo would scrap research into pain drugs for the same reasons, focusing instead on diseases including Alzheimer’s, Parkinson’s, multiple sclerosis and a clutch of rare diseases.

Read entire article:  http://online.wsj.com/article/SB10001424052748704041504575044901266169316.html

« Return to news items


Share

Manufacturing Depression: The secret history of science run amok, a lust for money & the manufacturing of a disease

Thursday, February 4th, 2010

The Brooklyn Rail
By Kaitlin Bell
February 2010

Gary Greenberg opens his new history of depression with a riveting tale of scientific ingenuity. A young, unknown marine biologist with an interest in mussels happens to discover the neurotransmitter serotonin and helps spur the antidepressant revolution. Lest we get too excited, though, Greenberg deflates our hopes just a few pages in.  Great science stories involve chance discoveries that change our everyday lives, he says—but this is not the kind of story he is going to tell.

Instead, the story that dominates Manufacturing Depression: The Secret History of a Disease is of scientific exuberance run amok, of coincidences and hasty conclusions, of a lust for money and for control over what Greenberg aptly describes as the landscape of mental suffering. Greenberg is outraged that “the depression doctors,” as he ominously terms them, have cornered the market on Americans’ internal anguish and have managed to convince millions of people that their unhappiness is actually a disease with a simple cause—a chemical imbalance—and a magic-bullet cure. It’s especially infuriating because this notion isn’t based in fact; it’s just a story we have allowed the medical establishment to tell us. There is no biochemical marker for depression, no good way to tell who is and who isn’t depressed. The tools doctors use to diagnose depression, as well as the other varieties of mental illness, are based on symptoms alone—whether someone is eating or sleeping more or less than usual, for example, or suffering from excessive guilt, or engaging in too much self-criticism.  Most of what’s diagnosed as depression is, in other words, nothing more than the name our society gives to a particular kind of emotional and mental suffering considered worthy of fixing.

In one sense, Greenberg has reclaimed the narrative very effectively. He has produced a tightly woven history showing that the medical establishment, despite claims to the contrary, knows almost nothing about the causes of depression from a scientific, biochemical, or neurological perspective.

Read entire article:  http://www.brooklynrail.org/2010/02/express/a-frustrating-mess

« Return to news items


Share